Next Article in Journal
Resistance to Ticks and the Path to Anti-Tick and Transmission Blocking Vaccines
Next Article in Special Issue
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity
Previous Article in Journal
In Vivo Production of HN Protein Increases the Protection Rates of a Minicircle DNA Vaccine against Genotype VII Newcastle Disease Virus
Previous Article in Special Issue
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
Review

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

1
Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea
2
ABL Bio Inc., Seongnam 13488, Korea
3
Biotechcenter, POSTECH, Pohang 37673, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Ralph A. Tripp
Vaccines 2021, 9(7), 724; https://doi.org/10.3390/vaccines9070724
Received: 30 April 2021 / Revised: 5 June 2021 / Accepted: 28 June 2021 / Published: 2 July 2021
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment)
Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential to improve clinical efficacy and safety further. Here, we describe four classes of BsAbs: (a) immune effector cell redirectors; (b) tumor-targeted immunomodulators; (c) dual immunomodulators; and (d) dual tumor-targeting BsAbs. This review describes each of these classes of BsAbs and presents examples of BsAbs in development. We reviewed the biological rationales and characteristics of BsAbs and summarized the current status and limitations of clinical development of BsAbs and strategies to overcome limitations. The field of BsAb-based cancer immunotherapy is growing, and more data from clinical trials are accumulating. Thus, BsAbs could be the next generation of new treatment options for cancer patients. View Full-Text
Keywords: bispecific antibody; cancer immunotherapy bispecific antibody; cancer immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

You, G.; Won, J.; Lee, Y.; Moon, D.; Park, Y.; Lee, S.H.; Lee, S.-W. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines 2021, 9, 724. https://doi.org/10.3390/vaccines9070724

AMA Style

You G, Won J, Lee Y, Moon D, Park Y, Lee SH, Lee S-W. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines. 2021; 9(7):724. https://doi.org/10.3390/vaccines9070724

Chicago/Turabian Style

You, Gihoon, Jonghwa Won, Yangsoon Lee, Dain Moon, Yunji Park, Sang H. Lee, and Seung-Woo Lee. 2021. "Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies" Vaccines 9, no. 7: 724. https://doi.org/10.3390/vaccines9070724

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop